Abstract
Background: Vaccines based on modified GnRH peptide variants can be an alternative treatment for advanced prostate cancer. However, the efficacy of the GnRH-based vaccine variants has been limited by their insufficient immunogenicity.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have